Table 2

Number of people with HIV initiated on various antiretroviral drugs by calendar year

CD4 cell count eligibility thresholds	≤200 cells/µL period (2004–2010)							≤350 cells/µL period (2011–2014)				≤500 cells/µL period (2015)	Universal test and treat (CD4 cell count not required as an eligibility criteria
	Roll out of ART programme in SA						Introduction of TDF			Introduction of FDC		≤500 cells/µL period (2015)				Introduction of DTG
	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020 (end date: 29 February)	Total
Baseline ART
First NRTI
TDF	74	136	215	416	715	871	4926	7515	8447	7537	8404	9658	11 241	12 311	10 228	12 463	2044	97 201
d4T	662	1119	1758	2296	3990	5585	3295	672	539	243	69	35	22	11	5	0	3	20 304
AZT	94	131	244	317	401	350	302	305	447	168	127	120	103	78	45	35	0	3267
ABC	4	6	4	12	18	12	79	103	101	121	121	100	139	157	152	73	7	1209
Second NRTI
FTC	38	57	92	207	392	266	372	679	869	5157	7984	9397	10 938	12 476	10 195	12 396	1632	73 147
3TC	786	1331	2120	2830	4723	6539	8228	7912	8658	2911	737	516	565	311	253	175	421	49 016
ddI	9	4	10	4	9	11	2	4	4	1	1	1	1	1	0	0	1	63
NNRTI
EFV	720	1174	1773	2313	3808	4894	6488	6810	7990	7528	8476	9745	11 384	12 244	10 276	12 489	1605	109 717
NVP	90	186	407	665	1217	1764	1943	1648	1424	428	168	104	44	39	42	11	2	10 182
InSTI
DTG	0	0	0	0	0	0	0	1	1	0	0	0	0	265	43	36	446	792
RAL	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1	0	4
PIs
LPV/r	21	30	39	56	93	129	145	125	114	114	75	61	73	72	81	28	1	1257
ATV/r	0	0	3	1	1	1	1	0	0	0	0	2	2	12	5	6	0	34
RTV*	3	2	1	6	4	29	23	12	5	0	1	0	2	1	1	0	0	90

*There is a possibility of misreporting on TIER.Net with RTV data. Complexity of combination with ATV as well as double dosing for tuberculosis. No patient is given RTV alone if adult.
ABC, abacavir; ART, antiretroviral therapy; ATV, ritonavir-boosted atazanavir; AZT, zidovudine; ddI, didanosine; d4T, stavudine; DTG, dolutegravir; EFV, efavirenz; FDC, fixed-dose combination; FTC, emtricitabine; InSTI, integrase strand transfer inhibitor; LPV/r, ritonavir-boosted lopinavir; NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; NVP, nevirapine; PI, protease inhibitor; RAL, raltegravir; RTV, ritonavir; SA, South Africa; 3TC, lamivudine; TDF, tenofovir.